News

FluidCloud gets $8.1M to reverse-engineer cloud environments and unlock true multicloud agility - SiliconANGLE ...
As organizations increasingly embrace the dynamic and scalable nature of multi-cloud environments to drive innovation and ...
By Katherine Hamilton Viatris's said on Friday that the trial of an ointment for people with blepharitis didn't meet its primary endpoint.
Investing.com -- Viatris Inc. (NASDAQ: VTRS) stock fell 3.6% after the company announced that its Phase 3 study of MR-139 for blepharitis did not meet its primary endpoint. The randomized, double ...
Topline results were announced from a phase 3 study evaluating secukinumab in adults with newly diagnosed or relapsing giant cell arteritis (GCA). Secukinumab is an interleukin-17A antagonist ...
We show you how you can prepare your environment, grant roles, and deploy Microsoft Defender for Endpoint. Stop threats faster and keep your systems safer.
Drowning in device sprawl, inconsistent policies and security blind spots? A longtime Microsoft expert shares how to untangle the chaos.
Shares of Altimmune tumbled after the company failed to achieve statistical significance on one of the dual primary endpoints in a recent trial evaluating its drug, pemvidutide, for metabolic ...
Bove testified before the Senate on Wednesday that he never advised DOJ lawyers to defy a federal court order. A whistleblower claims otherwise.
Alto Neuroscience’s phase 2 depression trial has missed its primary efficacy endpoint, as patients on the drug candidate fared no better on a measure of alertness and mood than their peers on ...
Learn why CISOs prefer Microsoft Defender for Endpoint to secure their device estate across Windows, Linux, macOS, iOS, Android, and IoT devices.